Hulvershorn, Leslie A. MD, MSc; Fosselman, David D.; Dickstein, Daniel P. MD; Janicak, Philip G. MD, Editor
Dr. Hulvershorn is Assistant Professor of Psychiatry & Chief of Pediatric Mood Disorders, and Mr. Fosselman is Indiana CTSI Summer Research Program Intern, Riley Hospital for Children, Section of Child and Adolescent Psychiatry, Indiana University School of Medicine, 705 Riley Hospital Dr, Rm 4300, Indianapolis, IN 46202; E-mail: [email protected]; and Dr. Dickstein is Assistant Professor of Psychiatry and Human Behavior and Director, Pediatric Mood, Imaging, & NeuroDevelopment (PediMIND) Program, Bradley Hospital, Alpert Medical School of Brown University, Department of Psychiatry and Human Behavior, East Providence, RI.
All faculty and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations related to this CME activity.
The authors have disclosed that the use of atypical antipsychotics, stimulants, antidepressants, and alpha agonists for treatment of children and adolescents as discussed in this article has not been approved by the U.S. Food and Drug Administration.
doi: 10.1097/01.PSYPHR.0000410254.32502.c5